

## Review Article

# Antioxidant Stress and Anti-Inflammation of PPAR $\alpha$ on Warm Hepatic Ischemia-Reperfusion Injury

**Zhixin Gao and Yuan-Hai Li**

*Department of Anesthesiology, First Affiliated Hospital of Anhui Medical University, Hefei 230022, China*

Correspondence should be addressed to Yuan-Hai Li, liyuanhai-1@163.com

Received 25 July 2012; Revised 27 September 2012; Accepted 10 October 2012

Academic Editor: Yasuteru Kondo

Copyright © 2012 Z. Gao and Y.-H. Li. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Hepatic ischemia-reperfusion (IR) injury is a serious clinical problem. Minimizing the adverse effect of ischemia-reperfusion injury after liver surgery or trauma is an urgent need. It has been proved that besides the effect of regulating the lipid and lipoprotein metabolism, PPAR $\alpha$  also undertakes the task of organ protection. In this paper, related literature has been summarized and we come to the conclusion that administration of PPAR $\alpha$  agonists can strengthen the antioxidant and anti-inflammation defense system by the upregulation of the expression of antioxidant enzymes and inhibition of NF- $\kappa$ B activity. This may provide a potential clinical treatment for hepatic ischemia-reperfusion injury.

## 1. Introduction

Hepatic ischemia reperfusion (IR) injury is an important clinical problem complicating liver surgery and transplantation [1]. Depending on whether the ischemia occurs in a warm setting, such as surgical resection or trauma surgery, or cold ischemia, as occurs during liver transplantation, it can be categorized into warm IR and cold storage reperfusion injury [2]. In warm IR, the pathophysiology underlying the injury of hepatic ischemia-reperfusion is complex encompassing a number of mechanisms including oxidant stress, inflammation, and apoptosis. Recently, some researchers have focused on the use of peroxisome proliferator-activated receptor alpha (PPAR $\alpha$ ) agonist to ameliorate this injury [3, 4]. In this paper, the mechanisms of hepatic ischemia-reperfusion injury, the characteristics of PPAR $\alpha$ , and the role of PPAR $\alpha$  in warm hepatic ischemia-reperfusion injury have been discussed in the following sections.

## 2. Mechanisms of Warm Hepatic Ischemia-Reperfusion Injury

With the growth in the field of hepatobiliary surgery, the technique of partial or total vascular occlusion in room temperature has been adapted, and it has enabled surgeons

to perform complex procedures such as large liver resections and repairs that otherwise would have resulted in massive hemorrhage and certain death. Apart from the apparent superiority of the technique, there are still some limitations that can cause substantial morbidity and mortality named warm hepatic ischemia-reperfusion injury. Warm hepatic ischemia-reperfusion injury is a complex cascade of events involving a multitude of pathophysiological processes, more than 50% of hepatocytes and sinusoidal endothelial cells (SEC) that formerly considered to undergo apoptosis during the first 24 hours of reperfusion [5, 6]; however, work done by team of Jaspreets Gujral suggested that apoptotic cell death, if it occurs at all, is a very minor aspect of the entire cell death [7, 8]. Based on it we can conclude that the oxidant stress and inflammation are the most critical mechanisms which contribute to the organ pathophysiology after warm hepatic ischemia reperfusion. Work done by Jaeschke et al. [9–12] indicated that there are two distinct phases of liver injury after warm ischemia and reperfusion. The initial phase of injury (<2 hours after reperfusion) is characterized by Kupffer cells activated, and the activated Kupffer cells are a primary source of reactive oxygen-derived free radicals [10, 13]. These free radicals and reactive oxygen species (ROS) are generated to create a severe enough disturbance of the cellular homeostasis. Mitochondria must be a primary

target, and its dysfunction may impair the electron flow and enhance superoxide formation [14, 15]. All these will eventually trigger mitochondrial dysfunction and oxidant stress and eventually kill the cell [16, 17]. Studies have shown that it attenuates early hepatocellular injury after hepatic IR that Kupffer cells activity is suppressed by gadolinium chloride or methyl palmitate in mice [18]. Conversely, chemically upregulating Kupffer cell activation aggravates cellular injury and production of reactive oxygen species [19]. In addition, complement is a key factor that contributes to the early activation of Kupffer cells after IR [20]. Kupffer cell generation of superoxide has been shown to be a decisive factor in the injury observed in the early reperfusion period [20, 21]. In addition to Kupffer cell-induced oxidant stress, with increasing length of the ischemic episode, intracellular generation of reactive oxygen by xanthine oxidase and, in particular, mitochondria [22] may also lead to impaired adenosine triphosphate (ATP) production and acidosis result in liver dysfunction and cell injury during reperfusion [23]. Nevertheless, liver architecture assessed histologically shows only minor changes during the period of ischemia and early reperfusion. In the late phase of injury (>6 hours after reperfusion), events occurring during the initial phased serve to initiate and propagate a complex inflammatory response that culminates with the hepatic accumulation of neutrophils [24]. Kupffer cells which can not only directly activate and recruit neutrophils but also serve as the principal source of the oxidant stress during the first period phase of reperfusion injury, the production, and the release of reactive oxygen species can lead to an oxidative shift in the hepatic redox state [10, 11, 25], that is thought to activate redox-sensitive transcription factor NF- $\kappa$ B, which provides the signal for activation of proinflammatory genes, such as IL-12 and TNF- $\alpha$  [26–29]. Productions of these mediators lead to inducing the expression of secondary mediators, including neutrophil-attracting CXC chemokines and endothelial cell adhesion molecules which mediate the adhesion and transmigration of neutrophils from the vascular space into the hepatic parenchyma [30–32]. Neutralizing antibodies to CXC chemokines proven to be effective against neutrophil-induced liver injury during ischemia reperfusion [33] and partial hepatectomy [34]. The priming of neutrophils during this time may be an important factor for the later neutrophil-induced injury phase [11]. Activated neutrophils generate two major cytotoxic mediators, that is, reactive oxygen species and proteases [21]. In addition to the NADPH oxidase-derived superoxide and its dismutation product hydrogen peroxide, data from Tadashi Hasegawa and his co-workers provide a direct evidence for a specific neutrophil-mediated oxidant stress [hypo-chlorite (HOCl)-modified epitopes] during reperfusion when a relevant number of neutrophils have extravasated into the parenchyma from sinusoids [21]. HOCl, generated only from H<sub>2</sub>O<sub>2</sub> and Cl<sup>−</sup> by myeloperoxidase (MPO), can diffuse into hepatocytes and cause formation of chloramines, which are potent oxidants and cytotoxic agents involved in hepatocytes killing and responsible for maintaining the inflammatory response [35]. In addition, neutrophils store various proteases in granules and can release these proteolytic enzymes during activation.

Protease inhibitors are shown to attenuate neutrophil-induced liver injury [36]. Moreover, reactive oxygen species are indispensable for a protease-mediated injury mechanism under in vivo conditions. Therefore, accumulated neutrophils release oxidants and proteases that directly injure hepatocytes and vascular endothelial cells and may also obstruct hepatic sinusoids resulting in hepatic hypoperfusion [37]. During the second phase of reperfusion injury, neutrophils work as the most acute cytotoxic inflammatory cells activated and recruited, and the damage caused by neutrophils is recognized as a major mechanism of during reperfusion [24, 38, 39]. A recent study by Beraza et al. has suggested that the hepatic inflammatory response to IR is driven largely by NF- $\kappa$ B activation in hepatocytes [40]. Nuclear factor (NF)- $\kappa$ B is a broad term used to describe a number of dimeric combinations of proteins of the Rel family [41, 42]. In unstimulated cells, NF- $\kappa$ B is sequestered in the cytoplasm by inhibitors of  $\kappa$ B (I $\kappa$ B) proteins which prevent nuclear localization of NF- $\kappa$ B by masking its nuclear localization signal peptide and block NF- $\kappa$ B from binding to DNA by allosteric inhibition [43]. Once is freed from I $\kappa$ B, NF- $\kappa$ B translocates to the nucleus where it initiates the transcription of target genes such as tumor necrosis factor- $\alpha$  (TNF- $\alpha$ ), interleukin (IL)-1b, and IL-6 [24, 44, 45]. The NF- $\kappa$ B inhibitory protein A20 demonstrates hepatoprotective abilities through curtailing inflammation by inhibiting NF- $\kappa$ B activation [46]. On the contrary, A20 knockout mice are born cachectic and die within 3 weeks of birth as a result of unfettered liver inflammation [47]. Therefore, above the literature provides compelling evidence that inhibition of oxidant-stress and inflammation in hepatocytes during IR injury is an essential mechanism of protection.

### 3. Characteristics of PPAR $\alpha$

PPAR is originally identified by Issemann and Green [48] after screening the liver cDNA library with a cDNA sequence located in the highly conserved C domain of nuclear hormone receptors. A notability subtype of PPAR will be discussed here is PPAR $\alpha$ . In human body, PPAR $\alpha$  gene which spans ~93.2 kb is located on chromosome 22q12-q13.1 and encodes a protein of 468 amino acids [49]. While in mice, PPAR $\alpha$  gene is located on chromosome 15E2, and it also encodes a protein of 468 amino acids [50]. PPAR $\alpha$  contains four major functional domains, which are the N-terminal ligand-independent transactivation domain (A/B domain), the DNA binding domain (DBD or C domain), the cofactor docking domain (D domain), and the C-terminal E/F domain (including the ligand binding domain (LBD) and the ligand-dependent transactivation domain (AF-2 domain) [51, 52]. The divergent amino acid sequence in the LBD of PPAR $\alpha$  is thought to provide the molecular basis for ligand selectivity. A large ligand-binding pocket (1300 Å) exists in PPAR $\alpha$ , allowing diverse and structurally distinct compounds access to the LBD [51] and enabling PPAR $\alpha$  to sense a broad range of endogenous substances, including fatty acids and their derivatives, or exogenous ligands, such as fibrates, Wy14643 [53, 54], and so on.

Analogous with several other nuclear hormone receptors, PPAR $\alpha$  also is a ligand-activated transcription factor which upon heterodimerization with the retinoic X receptor (RXR), recognizes PPAR response elements (PPRE), located in the promoter of target genes [55]. PPAR $\alpha$  is highly expressed in the liver, kidney, and heart muscle, which are all organs that possess high mitochondrial and  $\beta$ -oxidation activity. PPAR $\alpha$  basically function, as sensor for fatty acid derivatives and controls essential metabolic pathways involved in lipid and energy metabolism, and it also plays a significant role in various pathophysiologic conditions, such as inflammation and apoptosis caused by injury [56]. Our group and others have demonstrated that PPAR $\alpha$  is an important regulator of posts ischemic liver injury [3, 4].

#### 4. Roles of PPAR $\alpha$ on Warm Hepatic Ischemia-Reperfusion Injury

Reactive oxygen species and inflammation factors are critical mediators that exert a toxic effect during warm hepatic ischemia-reperfusion injury. Therefore, the most significant mechanisms of PPAR $\alpha$  hepatoprotective abilities have been demonstrated through antioxidant stress and anti-inflammation functions (Figure 1).

**4.1. Antioxidant Stress.** Interruption of blood flow to liver and subsequent reperfusion lead to an acute oxidant stress response that may cause significant cellular damage and organ dysfunction. Hepatocellular injury during both the initial and later phases of reperfusion is caused in large part by reactive oxygen species including hypochlorite (HOCl) [10, 11, 25]. Accordingly, antioxidant therapy can limit the ischemia-reperfusion injury [57, 58]. The discovery of the colocalization of catalase with H<sub>2</sub>O<sub>2</sub>-generating oxidases in peroxisomes is the chief indication of their involvement in the metabolism of oxygen metabolites [59]. Peroxisomes, which are subcellular organelles within the hepatocyte, contain a battery of antioxidant enzymes and may help protect hepatocytes from oxidative damage. Catalase is the classical marker enzyme of peroxisomes metabolizing both H<sub>2</sub>O<sub>2</sub> and a variety of substrates such as ethanol, methanol, phenol, and nitrites by peroxidatic activity [60], so it plays an important protective function against the toxic effects of peroxides and removes them with high efficiency [61]. PPAR $\alpha$  stimulation by Wy14643 induces expression and activation of antioxidant enzymes such as superoxide dismutase (SOD), catalase, and glutathione (GSH), which protects hepatocytes against hepatic IR injury mice model in vivo [3]. From the vitro experimental results of our group, the protective effect of Wy14643 is demonstrated herein by reducing ALT, AST, ROS levels and ameliorating ultrastructure alterations of hepatocytes; this protection is associated with an inhibition of oxidative stress and upregulation of hepatocytes PPAR $\alpha$ -mRNA expression [62]. PPAR $\alpha$  has also been implicated in the expression or activation of antioxidant enzymes such as catalase and Cu<sub>2</sub><sup>+</sup>, Zn<sub>2</sub><sup>+</sup> superoxide dismutase (SOD1) [63]. Work done by Tetsuya Toyama has indicated that PPAR $\alpha$  ligands (Wy14643) play an antifibrotic action through

disrupting the vicious cycle between hepatic damage and oxidative stress by activating antioxidant enzymes such as catalase, and resolving the oxidative stress in the rat TAA model of liver cirrhosis [63]. The PPAR $\alpha$  agonist is also highly effective in the treatment of dietary steatohepatitis in mice which results from the action of ROS on accumulated lipids and excessive formation of lipoperoxides in the liver [64]. Simultaneously, the improved antioxidant defense system after PPAR $\alpha$  activation can thus additionally protect against neutrophil cytotoxicity, and the related mechanism can be concluded that formation of ROS plays a key role in leading to hepatocytes necrosis mediated by neutrophil. After mice with 90 min ischemia and 8 h reperfusion, Tomohisa Okaya and Alex B. Lentsch have suggested that PPAR $\alpha$ <sup>-/-</sup> mice have augmented hepatocellular injury compared with wild-type mice, which is proved to be associated with a marked increase in the amount of neutrophils recruited to the liver, because at this time point much of the injury to hepatocytes is thought to be due to reactive oxygen species and proteases released from recruited neutrophils. On the contrary, treatment of C57BL/6 mice with 10 mg/kg iv WY-14643 1 h before ischemia resulted in a modest but significant reduction in hepatocellular injury [3]. Furthermore, antioxidants and other interventions directed toward detoxification of reactive oxygen species also attenuated inflammatory liver injury [12, 65–67]. The mechanism of PPAR $\alpha$  response to ROS is much more complex that it requires further research. At the same time, the regulation of antioxidant enzymes is closely related to apoptosis signaling [68]. Therefore, elevation of anti-oxidative enzymes can suppress apoptosis and this can also promote carcinogenesis [69].

**4.2. Anti-Inflammation.** Neutrophils are recruited from the vascular space through a complex series of events that involve upregulated expression of cellular adhesion molecules on hepatic vascular endothelial cells and increased production of CXC chemokines [31, 70]. Accumulated neutrophils release oxidants and proteases that directly and drastically injure hepatocytes and vascular endothelial cells [24]. The first evidence indicating a potential role for PPAR $\alpha$  in the inflammatory response is the demonstration that leukotriene B<sub>4</sub> (LTB<sub>4</sub>), a proinflammatory eicosanoid, binds to PPAR $\alpha$  and induces the transcription of genes involved in  $\omega$ - and  $\beta$ -oxidation which leads to the induction of its own catabolism [71]. In this respect, the activation of PPAR $\alpha$  by leukotriene B<sub>4</sub> serves to limit the inflammatory process, providing a physiological mechanism to stop the damaging effects associated with inflammation [72]. Numerous recent studies have been aimed at delineating the cellular and molecular mechanisms explaining the control of the inflammatory response by PPAR $\alpha$  in hepatic ischemia-reperfusion injury. Primarily according to previous studies by our group, the protective effects of PPAR $\alpha$  agonists (Wy14643) in posts ischemic liver injury are possibly associated with reductions in neutrophil accumulation, oxidative stress, and tumor necrosis factor (TNF) and interleukin-1 (IL-1) expression in livers during IR [4]. The results also have been supported by additional experimental results [38, 63]. Furthermore, works done by




FIGURE 1: Protection mechanism of PPARα in the liver during IR injury. Ischemic stress results in the generation of reactive oxygen species (ROS) in Kupffer cells. ROS activates NF-κB and induces mitochondrial dysfunction in neighboring hepatocytes. Activation of NF-κB consequences in the production of proinflammatory cytokines, chemokines and adhesion molecules which can recruit neutrophils and propagate the inflammatory response. This vicious circle is broken by PPARα which is a ligand-activated transcription factor that upon heterodimerization with the retinoic X receptor (RXR), recognizes PPAR response elements (PPRE), located in the promoter of target genes. Abbreviations: Neutrophil (N), Kupffer cell (KC).

Tomohisa Okaya and Alex B. Lentsch suggest that livers from PPARα<sup>-/-</sup> mice have significantly more postischemic injury compared with those from wild-type mice. A possible reason may be the augmented liver neutrophil accumulation and the modest increases in activation of the transcription factor NF-κB. Treatment of cultured murine hepatocytes with WY-14643, a specific agonist of PPARα, protected cells against oxidant-induced injury. However, there are no differences in proinflammatory mediator production between PPARα<sup>-/-</sup> and wild-type mice. These data suggest that PPARα is an important regulator of the hepatic inflammatory response to ischemia reperfusion in a manner that is independent of proinflammatory cytokines [3]. What's more, evidence from *in vitro* experiments for an anti-inflammatory action of PPARα in endothelial cells and monocytes also demonstrate, that PPARα ligands inhibit cytokine-induced genes, such as expression of vascular cell adhesion molecule-1 and tissue factor by downregulating the transcription of these genes [73–75]. Researches address the molecular mechanisms of this anti-inflammatory action demonstrate that PPARα negatively regulate the transcription of inflammatory response genes by antagonizing the nuclear factor-κB (NF-κB) signaling pathway [76]. In addition to the antagonistic

action on NF-κB signalling, PPARα activators are known to induce inhibitor of NF-κB, IκB-α, in primary smooth muscle cells and hepatocytes, which is associated with reduced NF-κB DNA binding triggered by PPARα [58]. N-3 polyunsaturated fatty acids (n-3 PUFA), eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) are considered as PPARα agonists and can also decrease the expression of proinflammatory genes by preventing IκB phosphorylation and NF-κB translocation into the nucleus [77]. Recent studies have suggested that liver preconditioning against IR injury by n-3PUFA supplementation is mediated by PPARα diminishing NF-κB DNA binding through direct protein-protein interaction with NF-κB subunit p65, leading to the recovery of NF-κB signalling activity and reestablishment of inflammatory cytokine homeostasis [78]. The zinc finger protein A20 [79], which is an intracellular ubiquitin-editing enzyme, plays a significant role in the negative feedback regulation of NF-κB activation in response to a diverse range of stimuli [80]. In lethal liver ischemia-reperfusion injury model, the survival rate of mice treated with A20 reached 67% compared with 10%–25% of control mice injected with saline. This major survival advantage in A20-treated mice is associated with protecting against liver IR injury



by increasing hepatic expression of PPAR $\alpha$ . A20-mediated protection of hepatocytes from hypoxia/reoxygenation and H<sub>2</sub>O<sub>2</sub>-mediated necrosis is reverted by pretreatment with the PPAR $\alpha$  inhibitor MK886 [81]. However, the reverse evidence published by Yu et al. [82] reported that inhibition of NF- $\kappa$ B activation by A20 aggravated partial hepatic ischemia-reperfusion injury. According to this report, Xu et al. suggested that NF- $\kappa$ B inactivation in hepatocytes switches the TNF- $\alpha$  response from proliferation to apoptosis, so decreased NF- $\kappa$ B activity sensitizes hepatocytes to TNF- $\alpha$ -induced cytotoxicity and may contribute to increased liver dysfunction [83]. In nonalcoholic steatohepatitis (NASH) and simple steatosis, besides reducing steatosis by regulation lipid and lipoprotein metabolism, treatment of mice with the PPAR $\alpha$  activator Wy14643 protects steatotic livers against IR injury, with the benefits of this treatment potentially occurring through dampening vascular cellular adhesion molecule-1 and cytokine responses and activation of NF- $\kappa$ B and IL-6 production [84]. The former contradictory results have suggested that the role of NF- $\kappa$ B activation during hepatic ischemia-reperfusion injury is controversial because it induces both protective and proinflammatory genes [85] and NF- $\kappa$ B inactivation either protects against hepatic IR injury [86–88] or aggravates such injury [45, 89, 90]. Studies done by Nozomu Sakai and Heather have indicated that activation of NF- $\kappa$ B in Kupffer cells promotes inflammation through cytokine expression, whereas activation in hepatocytes may be cell protective, based on the fact that they further proved that exogenous administration of receptor activator of NF- $\kappa$ B ligand (RANKL) reduces liver injury in a manner associated with increased hepatocyte NF- $\kappa$ B activation [91]. Supplementary works needed to be completed to explore how the PPAR $\alpha$  plays a role in directing a clinical outcome which may lead to better prospects of more rational approaches to reduce postischemic liver injury. In addition to all of the mentioned above, PPAR $\alpha$  is also a target of the hypothalamic hormone signaling as it plays an important role in the anti-inflammatory action of glucocorticoids [92].

## 5. Perspectives

As outlined in this paper, there is ample evidence for a critical involvement of oxidant-stress and inflammatory response in various animal models of hepatic ischemia-reperfusion injury. ROS are generated during initial reperfusion, where the initial cell damage triggers an inflammatory response with activation of tissue macrophages and recruitment of neutrophils both of them cause cell death and liver injury. Growing evidences for a role of PPAR $\alpha$  in a variety of physiological and pathological processes, particularly the participation in the pathophysiology of inflammation and the protective role of hepatic ischemia-reperfusion injury via limiting oxidative injury as well as inhibiting inflammation response, has emerged in prevenient researches. However, species-specific differences in response to PPAR $\alpha$  activators still exist between human and animals. Rats and mice are highly susceptible to peroxisome proliferation and are

susceptible to hepatocarcinogenesis due to the antiapoptosis of PPAR $\alpha$  activators. Whereas, PPAR $\alpha$  agonists are clinically and functionally relevant as fibrate therapeutics against hyperlipidemia and agents for reducing the complications of peripheral vascular disease in diabetic patients [93]. Yet, there are no sufficient evidence to show that hepatic cancer, hypertrophy, or peroxisome proliferation is relevant to it. On the contrary, PPAR $\alpha$  receptor activation can interrupt the development process of chronic hepatitis C and NASH to liver cancer by regulating the lipid and lipoprotein metabolism and enhancing the antioxidant stress. This is because obesity-related metabolic abnormalities [94], especially insulin resistance, may be a decisive factor in the pathogenesis of chronic hepatitis C as recently suggested in nonalcoholic steatohepatitis (NASH), along with impairment in lipid metabolism [95]. And the second reason is that oxidative stress not only damages hepatocytes and increases the rate of hepatocyte death, but also inhibits the replication of mature hepatocytes [96]. In order to balance the decreased replication capacity of mature hepatocytes, hepatic progenitors accumulate in the liver; this abnormal regenerative process may contribute to Hepatocellular Carcinoma.

One crucial difference is that the level of expression of PPAR $\alpha$  in the human liver is lower than that found in rats and mice [97]. It is also worth pointing out that long term exposure to these drugs can result in oxidative DNA damage, among other effects [92, 98]. So despite their potentially beneficial roles, PPAR $\alpha$  agonists should be used judiciously.

## References

- [1] J. C. Hong, D. Koroleff, V. Xia et al., "Regulated hepatic reperfusion mitigates ischemia-reperfusion injury and improves survival after prolonged liver warm ischemia: a pilot study on a novel concept of organ resuscitation in a large animal model," *Journal of the American College of Surgeons*, vol. 214, no. 4, pp. 505–515, 2012.
- [2] C. N. Clarke, A. D. Tevar, and A. B. Lentsch, "Hepatic ischemia/reperfusion injury," in *Molecular Pathology of Liver Diseases*, pp. 397–410, 2011.
- [3] T. Okaya and A. B. Lentsch, "Peroxisome proliferator-activated receptor- $\alpha$  regulates postischemic liver injury," *American Journal of Physiology*, vol. 286, no. 4, pp. G606–G612, 2004.
- [4] S. Q. Xu, Y. H. Li, S. H. Hu, K. Chen, and L. Y. Dong, "Effects of Wy14643 on hepatic ischemia reperfusion injury in rats," *World Journal of Gastroenterology*, vol. 14, no. 45, pp. 6936–6942, 2008.
- [5] R. Cursio, J. Gugenheim, J. E. Ricci et al., "A caspase inhibitor fully protects rats against lethal normothermic liver ischemia by inhibition of liver apoptosis," *The FASEB Journal*, vol. 13, no. 2, pp. 253–261, 1999.
- [6] V. Kohli, J. F. Madden, R. C. Bentley, P. A. Clavien, and M. Selzner, "Endothelial cell and hepatocyte deaths occur by apoptosis after ischemia-reperfusion injury in the rat liver," *Transplantation*, vol. 67, no. 8, pp. 1099–1105, 1999.
- [7] J. S. Gujral, T. J. Bucci, A. Farhood, and H. Jaeschke, "Mechanism of cell death during warm hepatic ischemia-reperfusion in rats: apoptosis or necrosis?" *Hepatology*, vol. 33, no. 2, pp. 397–405, 2001.

- [8] H. Jaeschke and J. J. Lemasters, "Apoptosis versus oncotic necrosis in hepatic ischemia/reperfusion injury," *Gastroenterology*, vol. 125, no. 4, pp. 1246–1257, 2003.
- [9] H. Jaeschke, C. V. Smith, and J. R. Mitchell, "Reactive oxygen species during ischemia-reflow injury in isolated perfused rat liver," *The Journal of Clinical Investigation*, vol. 81, no. 4, pp. 1240–1246, 1988.
- [10] H. Jaeschke and A. Farhood, "Neutrophil and Kupffer cell-induced oxidant stress and ischemia-reperfusion injury in rat liver," *American Journal of Physiology*, vol. 260, no. 3, pp. G355–G362, 1991.
- [11] H. Jaeschke, A. P. Bautista, Z. Spolarics, and J. J. Spitzer, "Superoxide generation by Kupffer cells and priming of neutrophils during reperfusion after hepatic ischemia," *Free Radical Research Communications*, vol. 15, no. 5, pp. 277–284, 1991.
- [12] H. Jaeschke, "Reactive oxygen and ischemia/reperfusion injury of the liver," *Chemico-Biological Interactions*, vol. 79, no. 2, pp. 115–136, 1991.
- [13] H. Jaeschke, A. P. Bautista, Z. Spolarics, and J. J. Spitzer, "Superoxide generation by neutrophils and Kupffer cells during *in vivo* reperfusion after hepatic ischemia in rats," *Journal of Leukocyte Biology*, vol. 52, no. 4, pp. 377–382, 1992.
- [14] H. Jaeschke and J. R. Mitchell, "Mitochondria and xanthine oxidase both generate reactive oxygen species in isolated perfused rat liver after hypoxic injury," *Biochemical and Biophysical Research Communications*, vol. 160, no. 1, pp. 140–147, 1989.
- [15] H. Jaeschke, "Antioxidant defense mechanisms," in *Comprehensive Toxicology*, vol. 9, pp. 319–337, 2010.
- [16] A. L. Nieminen, A. M. Byrne, B. Herman, and J. J. Lemasters, "Mitochondrial permeability transition in hepatocytes induced by t-BuOOH: NAD(P)H and reactive oxygen species," *American Journal of Physiology*, vol. 272, no. 4, pp. C1286–C1294, 1997.
- [17] A. Uchiyama, J. S. Kim, K. Kon et al., "Translocation of iron from lysosomes into mitochondria is a key event during oxidative stress-induced hepatocellular injury," *Hepatology*, vol. 48, no. 5, pp. 1644–1654, 2008.
- [18] P. Liu, G. M. McGuire, M. A. Fisher, A. Farhood, C. W. Smith, and H. Jaeschke, "Activation of Kupffer cells and neutrophils for reactive oxygen formation is responsible for endotoxin-enhanced liver injury after hepatic ischemia," *Shock*, vol. 3, no. 1, pp. 56–62, 1995.
- [19] I. Kurose, R. Wolf, M. B. Grisham, and D. N. Granger, "Modulation of ischemia/reperfusion-induced microvascular dysfunction by nitric oxide," *Circulation Research*, vol. 74, no. 3, pp. 376–382, 1994.
- [20] H. Jaeschke, A. Farhood, A. P. Bautista, Z. Spolarics, and J. J. Spitzer, "Complement activates Kupffer cells and neutrophils during reperfusion after hepatic ischemia," *American Journal of Physiology*, vol. 264, no. 4, pp. G801–G809, 1993.
- [21] H. Jaeschke and C. W. Smith, "Mechanisms of neutrophil-induced parenchymal cell injury," *Journal of Leukocyte Biology*, vol. 61, no. 6, pp. 647–653, 1997.
- [22] I. Grattagliano, G. Vendemiale, and B. H. Lauterburg, "Reperfusion injury of the liver: role of mitochondria and protection by glutathione ester," *Journal of Surgical Research*, vol. 86, no. 1, pp. 2–8, 1999.
- [23] Y. Kumamoto, M. Suematsu, M. Shimazu et al., "Kupffer cell-independent acute hepatocellular oxidative stress and decreased bile formation in post-cold-ischemic rat liver," *Hepatology*, vol. 30, no. 6, pp. 1454–1463, 1999.
- [24] A. B. Lentsch, A. Kato, H. Yoshidome, K. M. McMasters, and M. J. Edwards, "Inflammatory mechanisms and therapeutic strategies for warm hepatic ischemia/reperfusion injury," *Hepatology*, vol. 32, no. 2, pp. 169–173, 2000.
- [25] H. Jaeschke, "Molecular mechanisms of hepatic ischemia-reperfusion injury and preconditioning," *American Journal of Physiology*, vol. 284, no. 1, pp. G15–G26, 2003.
- [26] L. M. Colletti, D. G. Remick, G. D. Burtch, S. L. Kunkel, R. M. Strieter, and D. A. Campbell, "Role of tumor necrosis factor- $\alpha$  in the pathophysiologic alterations after hepatic ischemia/reperfusion injury in the rat," *The Journal of Clinical Investigation*, vol. 85, no. 6, pp. 1936–1943, 1990.
- [27] A. B. Lentsch, H. Yoshidome, A. Kato et al., "Requirement for interleukin-12 in the pathogenesis of warm hepatic ischemia/reperfusion injury in mice," *Hepatology*, vol. 30, no. 6, pp. 1448–1453, 1999.
- [28] T. Loop and H. Pahl, "Activators and target genes of Rel/NF- $\kappa$ B transcription factors," in *Nuclear Factor  $\kappa$ B: Regulation and Role in Disease*, pp. 1–48, 2003.
- [29] R. M. Zwacka, Y. Zhang, W. Zhou, J. Halldorson, and J. E. Engelhardt, "Ischemia/reperfusion injury in the liver of BALB/c mice activates AP-1 and nuclear factor  $\kappa$ B independently of I $\kappa$ B degradation," *Hepatology*, vol. 28, no. 4, pp. 1022–1030, 1998.
- [30] L. M. Colletti, A. Cortis, N. Lukacs, S. L. Kunkel, M. Green, and R. M. Strieter, "Tumor necrosis factor up-regulates intercellular adhesion molecule 1, which is important in the neutrophil-dependent lung and liver injury associated with hepatic ischemia and reperfusion in the rat," *Shock*, vol. 10, no. 3, pp. 182–191, 1998.
- [31] L. M. Colletti, S. L. Kunkel, A. Walz et al., "Chemokine expression during hepatic ischemia/reperfusion-induced lung injury in the rat. The role of epithelial neutrophil activating protein," *The Journal of Clinical Investigation*, vol. 95, no. 1, pp. 134–141, 1995.
- [32] A. B. Lentsch, H. Yoshidome, W. G. Cheadle, F. N. Miller, and M. J. Edwards, "Chemokine involvement in hepatic ischemia/reperfusion injury in mice: roles for macrophage inflammatory protein-2 and KC," *Hepatology*, vol. 27, no. 4, pp. 1172–1177, 1998.
- [33] L. M. Colletti, S. L. Kunkel, A. Walz et al., "The role of cytokine networks in the local liver injury following hepatic ischemia/reperfusion in the rat," *Hepatology*, vol. 23, no. 3, pp. 506–514, 1996.
- [34] L. M. Colletti, S. L. Kunkel, M. Green, M. Burdick, and R. M. Strieter, "Hepatic inflammation following 70% hepatectomy may be related to up-regulation of epithelial neutrophil activating protein-78," *Shock*, vol. 6, no. 6, pp. 397–402, 1996.
- [35] M. Bilzer and B. H. Lauterburg, "Effects of hypochlorous acid and chloramines on vascular resistance, cell integrity, and biliary glutathione disulfide in the perfused rat liver: modulation by glutathione," *Journal of Hepatology*, vol. 13, no. 1, pp. 84–89, 1991.
- [36] X. K. Li, A. F. Mohammad Matin, H. Suzuki, T. Uno, T. Yamaguchi, and Y. Harada, "Effect of protease inhibitor on ischemia/reperfusion injury of the rat liver," *Transplantation*, vol. 56, no. 6, pp. 1331–1336, 1993.
- [37] J. X. Zhang, D. V. Jones, and M. G. Clemens, "Effect of activation on neutrophil-induced hepatic microvascular

- injury in isolated rat liver," *Shock*, vol. 1, no. 4, pp. 273–278, 1994.
- [38] R. Di Paola and S. Cuzzocrea, "Peroxisome proliferator-activated receptors ligands and ischemia-reperfusion injury," *Naunyn-Schmiedeberg's Archives of Pharmacology*, vol. 375, no. 3, pp. 157–175, 2007.
  - [39] F. Serracino-Inglott, N. A. Habib, and R. T. Mathie, "Hepatic ischemia-reperfusion injury," *The American Journal of Surgery*, vol. 181, no. 2, pp. 160–166, 2001.
  - [40] N. Beraza, T. Lüdde, U. Assmus, T. Roskams, S. V. Borgh, and C. Trautwein, "Hepatocyte-specific IKK $\gamma$ /NEMO expression determines the degree of liver injury," *Gastroenterology*, vol. 132, no. 7, pp. 2504–2517, 2007.
  - [41] S. Ghosh, M. J. May, and E. B. Kopp, "NF- $\kappa$ B and Rel proteins: evolutionarily conserved mediators of immune responses," *Annual Review of Immunology*, vol. 16, pp. 225–260, 1998.
  - [42] M. J. May and S. Ghosh, "Signal transduction through NF- $\kappa$ B," *Immunology Today*, vol. 19, no. 2, pp. 80–88, 1998.
  - [43] C. Scheidereit, "I $\kappa$ B kinase complexes: gateways to NF- $\kappa$ B activation and transcription," *Oncogene*, vol. 25, no. 51, pp. 6685–6705, 2006.
  - [44] Y. Takahashi, R. W. Ganster, A. Gambotto et al., "Role of NF- $\kappa$ B on liver cold ischemia-reperfusion injury," *American Journal of Physiology*, vol. 283, no. 5, pp. G1175–G1184, 2002.
  - [45] T. Okaya and A. B. Lentsch, "Hepatic expression of S32A/S36A I $\kappa$ B $\alpha$  does not reduce postischemic liver injury," *Journal of Surgical Research*, vol. 124, no. 2, pp. 244–249, 2005.
  - [46] I. E. Wartz, K. M. O'Rourke, H. Zhou et al., "Deubiquitination and ubiquitin ligase domains of A20 downregulate NF- $\kappa$ B signalling," *Nature*, vol. 430, no. 7000, pp. 694–699, 2004.
  - [47] E. G. Lee, D. L. Boone, S. Chai et al., "Failure to regulate TNF-induced NF- $\kappa$ B and cell death responses in A20-deficient mice," *Science*, vol. 289, no. 5488, pp. 2350–2354, 2000.
  - [48] I. Issemann and S. Green, "Activation of a member of the steroid hormone receptor superfamily by peroxisome proliferators," *Nature*, vol. 347, no. 6294, pp. 645–650, 1990.
  - [49] B. Desvergne and W. Wahli, "Peroxisome proliferator-activated receptors: nuclear control of metabolism," *Endocrine Reviews*, vol. 20, no. 5, pp. 649–688, 1999.
  - [50] S. R. Pyper, N. Viswakarma, S. Yu, and J. K. Reddy, "PPAR $\alpha$ : energy combustion, hypolipidemia, inflammation and cancer," *Nuclear Receptor Signaling*, vol. 8, article e002, 2010.
  - [51] D. Moras and H. Gronemeyer, "The nuclear receptor ligand-binding domain: structure and function," *Current Opinion in Cell Biology*, vol. 10, no. 3, pp. 384–391, 1998.
  - [52] J. M. Lehmann, J. M. Lenhard, B. B. Oliver, G. M. Ringold, and S. A. Kliewer, "Peroxisome proliferator-activated receptors  $\alpha$  and  $\gamma$  are activated by indomethacin and other non-steroidal anti-inflammatory drugs," *The Journal of Biological Chemistry*, vol. 272, no. 6, pp. 3406–3410, 1997.
  - [53] Y. F. Guan and M. D. Breyer, "Peroxisome proliferator-activated receptors (PPARs): novel therapeutic targets in renal disease," *Kidney International*, vol. 60, no. 1, pp. 14–30, 2001.
  - [54] L. A. Cowart, S. Wei, M. H. Hsu et al., "The CYP4A isoforms hydroxylate epoxyeicosatrienoic acids to form high affinity peroxisome proliferator-activated receptor ligands," *The Journal of Biological Chemistry*, vol. 277, no. 38, pp. 35105–35112, 2002.
  - [55] J. C. Fruchart, B. Staels, and P. Duriez, "The role of fibric acids in atherosclerosis," *Current Atherosclerosis Reports*, vol. 3, no. 1, pp. 83–92, 2001.
  - [56] T. Maeda and S. Kishioka, "PPAR and Pain," *International Review of Neurobiology*, vol. 85, pp. 165–177, 2009.
  - [57] M. D. Wheeler, M. Katuna, O. M. Smutney et al., "Comparison of the effect of adenoviral delivery of three superoxide dismutase genes against hepatic ischemia-reperfusion injury," *Human Gene Therapy*, vol. 12, no. 18, pp. 2167–2177, 2001.
  - [58] G. K. Glantzounis, H. J. Salacinski, W. Yang, B. R. Davidson, and A. M. Seifalian, "The contemporary role of antioxidant therapy in attenuating liver ischemia-reperfusion injury: a review," *Liver Transplantation*, vol. 11, no. 9, pp. 1031–1047, 2005.
  - [59] M. Schrader and H. D. Fahimi, "Peroxisomes and oxidative stress," *Biochimica et Biophysica Acta*, vol. 1763, no. 12, pp. 1755–1766, 2006.
  - [60] N. Oshino, B. Chance, H. Sies, and T. Bücher, "The role of H<sub>2</sub>O<sub>2</sub> generation in perfused rat liver and the reaction of catalase compound I and hydrogen donors," *Archives of Biochemistry and Biophysics*, vol. 154, no. 1, pp. 117–131, 1973.
  - [61] A. G. Siraki, J. Pourahmad, T. S. Chan, S. Khan, and P. J. O'Brien, "Endogenous and endobiotic induced reactive oxygen species formation by isolated hepatocytes," *Free Radical Biology and Medicine*, vol. 32, no. 1, pp. 2–10, 2002.
  - [62] C. Ke, L. Yuan-Hai, X. Si-Qi et al., "Protective effects of peroxisome proliferator-activated receptor- $\alpha$  agonist, Wy14643, on hypoxia/reoxygenation injury in primary rat hepatocytes," *PPAR Research*, vol. 2012, Article ID 547980, 8 pages, 2012.
  - [63] T. Toyama, H. Nakamura, Y. Harano et al., "PPAR $\alpha$  ligands activate antioxidant enzymes and suppress hepatic fibrosis in rats," *Biochemical and Biophysical Research Communications*, vol. 324, no. 2, pp. 697–704, 2004.
  - [64] E. Ip, G. C. Farrell, G. Robertson, P. Hall, R. Kirsch, and I. Leclercq, "Central role of PPAR $\alpha$ -dependent hepatic lipid turnover in dietary steatohepatitis in mice," *Hepatology*, vol. 38, no. 1, pp. 123–132, 2003.
  - [65] T. Hasegawa, E. Malle, A. Farhood, and H. Jaeschke, "Generation of hypochlorite-modified proteins by neutrophils during ischemia-reperfusion injury in rat liver: attenuation by ischemic preconditioning," *American Journal of Physiology*, vol. 289, no. 4, pp. G760–G767, 2005.
  - [66] T. W. Wu, N. Hashimoto, J. X. Au, J. Wu, D. A. G. Mickle, and D. Carey, "Trolox protects rat hepatocytes against oxyradical damage and the ischemic rat liver from reperfusion injury," *Hepatology*, vol. 13, no. 3, pp. 575–580, 1991.
  - [67] B. Halliwell, "Role of free radicals in the neurodegenerative diseases: therapeutic implications for antioxidant treatment," *Drugs and Aging*, vol. 18, no. 9, pp. 685–716, 2001.
  - [68] F. McCormick, "Signalling networks that cause cancer," *Trends in Genetics*, vol. 15, no. 12, pp. M53–M56, 1999.
  - [69] G. B. Corcoran, L. Fix, D. P. Jones et al., "Apoptosis: molecular control point in toxicity," *Toxicology and Applied Pharmacology*, vol. 128, no. 2, pp. 169–181, 1994.
  - [70] L. M. Colletti, A. Cortis, N. Lukacs, S. L. Kunkel, M. Green, and R. M. Strieter, "Tumor necrosis factor up-regulates intercellular adhesion molecule 1, which is important in the neutrophil-dependent lung and liver injury associated with hepatic ischemia and reperfusion in the rat," *Shock*, vol. 10, no. 3, pp. 182–191, 1998.
  - [71] P. R. Devchand, H. Keller, J. M. Peters, M. Vazquez, F. J. Gonzalez, and W. Wahli, "The PPAR $\alpha$ -leukotriene B<sub>4</sub> pathway to inflammation control," *Nature*, vol. 384, no. 6604, pp. 39–43, 1996.



- [72] P. R. Devchand, O. Ziouzenkova, and J. Plutzky, "Oxidative stress and peroxisome proliferator-activated receptors: reversing the curse?" *Circulation Research*, vol. 95, no. 12, pp. 1137–1139, 2004.
- [73] P. Delerive, J. C. Fruchart, and B. Staels, "Peroxisome proliferator-activated receptors in inflammation control," *Journal of Endocrinology*, vol. 169, no. 3, pp. 453–459, 2001.
- [74] N. Marx, G. K. Sukhova, T. Collins, P. Libby, and J. Plutzky, "PPAR $\alpha$  activators inhibit cytokine-induced vascular cell adhesion molecule-1 expression in human endothelial cells," *Circulation*, vol. 99, no. 24, pp. 3125–3131, 1999.
- [75] B. P. Neve, D. Corseaux, G. Chinetti et al., "PPAR $\alpha$  agonists inhibit tissue factor expression in human monocytes and macrophages," *Circulation*, vol. 103, no. 2, pp. 207–212, 2001.
- [76] P. Delerive, P. Gervois, J. C. Fruchart, and B. Staels, "Induction of IkB $\alpha$  expression as a mechanism contributing to the anti-inflammatory activities of peroxisome proliferator-activated receptor- $\alpha$  activators," *The Journal of Biological Chemistry*, vol. 275, no. 47, pp. 36703–36707, 2000.
- [77] Y. Adkins and D. S. Kelley, "Mechanisms underlying the cardioprotective effects of omega-3 polyunsaturated fatty acids," *The Journal of Nutritional Biochemistry*, vol. 21, no. 9, pp. 781–792, 2010.
- [78] J. Zúñiga, M. Cancino, F. Medina et al., "N-3 PUFA supplementation triggers PPAR- $\alpha$  activation and PPAR- $\alpha$ /NF- $\kappa$ B interaction: anti-inflammatory implications in liver ischemia-reperfusion injury," *PLoS ONE*, vol. 6, no. 12, Article ID e28502, 2011.
- [79] A. Opipari Jr., M. S. Boguski, and V. M. Dixit, "The A20 cDNA induced by tumor necrosis factor  $\alpha$  encodes a novel type of zinc finger protein," *The Journal of Biological Chemistry*, vol. 265, no. 25, pp. 14705–14708, 1990.
- [80] B. Coornaert, I. Carpentier, and R. Beyaert, "A20: central gatekeeper in inflammation and immunity," *The Journal of Biological Chemistry*, vol. 284, no. 13, pp. 8217–8221, 2009.
- [81] H. E. Ramsey, C. G. Da Silva, C. R. Longo et al., "A20 protects mice from lethal liver ischemia/reperfusion injury by increasing peroxisome proliferator-activated receptor- $\alpha$  expression," *Liver Transplantation*, vol. 15, no. 11, pp. 1613–1621, 2009.
- [82] J. Yu, H. S. Lee, S. M. Lee et al., "Aggravation of post-ischemic liver injury by overexpression of A20, an NF- $\kappa$ B suppressor," *Journal of Hepatology*, vol. 55, no. 2, pp. 328–336, 2011.
- [83] Y. Xu, S. Bialik, B. E. Jones et al., "NF- $\kappa$ B inactivation converts a hepatocyte cell line TNF- $\alpha$  response from proliferation to apoptosis," *American Journal of Physiology*, vol. 275, no. 4, part 1, pp. C1058–C1066, 1998.
- [84] N. C. Teoh, J. Williams, J. Hartley, J. Yu, R. S. McCuskey, and G. C. Farrell, "Short-term therapy with peroxisome proliferation-activator receptor-agonist Wy-14,643 protects murine fatty liver against ischemia-reperfusion injury," *Hepatology*, vol. 51, no. 3, pp. 996–1006, 2010.
- [85] T. Luedde and C. Trautwein, "Intracellular survival pathways in the liver," *Liver International*, vol. 26, no. 10, pp. 1163–1174, 2006.
- [86] T. Luedde, U. Assmus, T. Wüstefeld et al., "Deletion of IKK2 in hepatocytes does not sensitize these cells to TNF-induced apoptosis but protects from ischemia/reperfusion injury," *The Journal of Clinical Investigation*, vol. 115, no. 4, pp. 849–859, 2005.
- [87] N. Matsui, K. Kasajima, M. Hada et al., "Inhibition of NF- $\kappa$ B activation during ischemia reduces hepatic ischemia/reperfusion injury in rats," *The Journal of Toxicological Sciences*, vol. 30, no. 2, pp. 103–110, 2005.
- [88] H. Suetsugu, Y. Iimuro, T. Uehara et al., "Nuclear factor  $\kappa$ B inactivation in the rat liver ameliorates short term total warm ischaemia/reperfusion injury," *Gut*, vol. 54, no. 6, pp. 835–842, 2005.
- [89] S. Kuboki, T. Okaya, R. Schuster et al., "Hepatocyte NF- $\kappa$ B activation is hepatoprotective during ischemia-reperfusion injury and is augmented by ischemic hypothermia," *American Journal of Physiology*, vol. 292, no. 1, pp. G201–G207, 2007.
- [90] S. Kuboki, N. Sakai, C. Clarke et al., "The peptidyl-prolyl isomerase, Pin1, facilitates NF- $\kappa$ B binding in hepatocytes and protects against hepatic ischemia/reperfusion injury," *Journal of Hepatology*, vol. 51, no. 2, pp. 296–306, 2009.
- [91] N. Sakai, H. L. Van Sweringen, R. Schuster et al., "Receptor activator of nuclear factor- $\kappa$ B ligand (RANKL) protects against hepatic ischemia/reperfusion injury in mice," *Hepatology*, vol. 55, no. 3, pp. 888–897, 2012.
- [92] C. Crisafulli, S. Bruscoli, E. Esposito et al., "PPAR- $\alpha$  contributes to the anti-inflammatory activity of 17 $\beta$ -estradiol," *Journal of Pharmacology and Experimental Therapeutics*, vol. 331, no. 3, pp. 796–807, 2009.
- [93] A. A. Bulhak, C. Jung, C. G. Östenson, J. O. Lundberg, P. O. Sjoquist, and J. Pernow, "PPAR- $\alpha$  activation protects the type 2 diabetic myocardium against ischemia-reperfusion injury: involvement of the PI3-kinase/Akt and NO pathway," *American Journal of Physiology*, vol. 296, no. 3, pp. H719–H727, 2009.
- [94] S. Yang, H. Z. Lin, J. Hwang, V. P. Chacko, and A. M. Diehl, "Hepatic hyperplasia in noncirrhotic fatty livers: is obesity-related hepatic steatosis a premalignant condition?" *Cancer Research*, vol. 61, no. 13, pp. 5016–5023, 2001.
- [95] K. Koike, "Hepatitis C as a metabolic disease: implication for the pathogenesis of NASH," *Hepatology Research*, vol. 33, no. 2, pp. 145–150, 2005.
- [96] S. Q. Yang, A. K. Mandal, J. Huang, and A. M. Diehl, "Disrupted signaling and inhibited regeneration in obese mice with fatty livers: implications for nonalcoholic fatty liver disease pathophysiology," *Hepatology*, vol. 34, no. 4, part 1, pp. 694–706, 2001.
- [97] P. R. Holden and J. D. Tugwood, "Peroxisome proliferator-activated receptor alpha: role in rodent liver cancer and species differences," *Journal of Molecular Endocrinology*, vol. 22, no. 1, pp. 1–8, 1999.
- [98] I. Rusyn, S. Asakura, B. Pachkowski et al., "Expression of base excision DNA repair genes is a sensitive biomarker for *in vivo* detection of chemical-induced chronic oxidative stress," *Cancer Research*, vol. 64, no. 3, pp. 1050–1057, 2004.



